Atrophic Vaginitis

tammyH64

Thiis a real thing. It becomes a problem when Estrogen levels decline with age. It is a real problem when you are being treated for ER and PR positive breast cancer. Tamoxifen or the others do what they can to starve the cancer cells. Is that what we are faced with? Cancer cells at bay and have itchy cottage cheese crotch? Science has have to come up with something more acceptable by now.

macb04

Lots of women with bc history get vaginal estrogen. That has been seen to be safe, even in the setting of ER/PR bc.

ACOG Supports the Use of Estrogen for Breast Cancer Survivors

February 22, 2016

Washington, DC — With 2 million breast cancer survivors now living in the United States, there is growing recognition among health care providers that quality of life issues for these women should be assessed and treated.

Today, in a new Committee Opinion, "The Use of Vaginal Estrogen in Women with a History of Estrogen-Dependent Breast Cancer," the American College of Obstetricians and Gynecologists (ACOG) outlines the options and treatments for female-specific survivorship issues. One particular challenge for providers to understand and address are vaginal symptoms of menopause, whether naturally occurring or treatment-induced.

Many therapies that treat estrogen-dependent breast cancer cause vaginal atrophy and increase symptoms of vaginal dryness, bleeding, bacterial infections and painful sex. These symptoms may worsen over time and, as women live longer, may pose significant challenges. It is estimated that up to 20% of all patients terminate or consider terminating therapies due to the severe detrimental effect that vaginal atrophy poses on their quality of life.

According to the new Committee Opinion, for women with estrogen-dependent breast cancer or a history of estrogen-dependent breast cancer, non-hormonal options for vaginal atrophy should be the first choice. However, health practitioners may now consider topical estrogen therapy for patients with a history of estrogen-dependent breast cancer who are unresponsive to non-hormonal remedies. Although there is controversy related to the risk of topical estrogen therapy and breast cancer recurrence, the Committee Opinion notes that data show there is no increased risk of cancer recurrence with the use of topical vaginal estrogen.

Diana Nancy Contreras, MD, Chair of ACOG's Subcommittee on Gynecologic Oncology, stated, "These new recommendations are especially important and helpful because they provide the patient with the information needed to make an informed decision with the input of her health care provider."

macb04

Lots of women with bc history get vaginal estrogen. That has been seen to be safe, even in the setting of ER/PR bc.

ACOG Supports the Use of Estrogen for Breast Cancer Survivors

February 22, 2016

Washington, DC — With 2 million breast cancer survivors now living in the United States, there is growing recognition among health care providers that quality of life issues for these women should be assessed and treated.

Today, in a new Committee Opinion, "The Use of Vaginal Estrogen in Women with a History of Estrogen-Dependent Breast Cancer," the American College of Obstetricians and Gynecologists (ACOG) outlines the options and treatments for female-specific survivorship issues. One particular challenge for providers to understand and address are vaginal symptoms of menopause, whether naturally occurring or treatment-induced.

Many therapies that treat estrogen-dependent breast cancer cause vaginal atrophy and increase symptoms of vaginal dryness, bleeding, bacterial infections and painful sex. These symptoms may worsen over time and, as women live longer, may pose significant challenges. It is estimated that up to 20% of all patients terminate or consider terminating therapies due to the severe detrimental effect that vaginal atrophy poses on their quality of life.

According to the new Committee Opinion, for women with estrogen-dependent breast cancer or a history of estrogen-dependent breast cancer, non-hormonal options for vaginal atrophy should be the first choice. However, health practitioners may now consider topical estrogen therapy for patients with a history of estrogen-dependent breast cancer who are unresponsive to non-hormonal remedies. Although there is controversy related to the risk of topical estrogen therapy and breast cancer recurrence, the Committee Opinion notes that data show there is no increased risk of cancer recurrence with the use of topical vaginal estrogen.

Diana Nancy Contreras, MD, Chair of ACOG's Subcommittee on Gynecologic Oncology, stated, "These new recommendations are especially important and helpful because they provide the patient with the information needed to make an informed decision with the input of her health care provider."

sas-schatzi

Bump